Alexza Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXA)   Watch this stock  
Find more results for ALXA
0.980
+0.060 (6.51%)
May 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.86 - 0.99
52 week 0.86 - 5.27
Open 0.86
Vol / Avg. 0.00/83,077.00
Mkt cap 17.87M
P/E     -
Div/yield     -
EPS -1.48
Shares 19.42M
Beta 0.99
Inst. own 34%
Aug 5, 2015
Q2 2015 Alexza Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 23, 2015
Alexza Pharmaceuticals Inc Annual Shareholders Meeting - 2:00PM EDT - Add to calendar
May 6, 2015
Q1 2015 Alexza Pharmaceuticals Inc Earnings Call
May 6, 2015
Q1 2015 Alexza Pharmaceuticals Inc Earnings Release
Mar 10, 2015
Alexza Pharmaceuticals Inc at ROTH Conference
Mar 9, 2015
Q4 2014 Alexza Pharmaceuticals Inc Earnings Call
Mar 9, 2015
Q4 2014 Alexza Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -57.30% -660.53%
Operating margin -1844.40% -673.55%
EBITD margin - -612.53%
Return on average assets -3.09% -67.63%
Return on average equity - -
Employees 81 -
CDP Score - -

Address

2091 Stierlin Ct
MOUNTAIN VIEW, CA 94043-4655
United States - Map
+1-650-9447000 (Phone)
+1-650-9447999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. Alexza’s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. The Company has one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. Its product candidates not in active development are AZ-007 (Staccato zaleplon), AZ-104 (Staccato loxapine, low-dose) AZ-003 (Staccato fentanyl) and AZ-003 (Staccato fentanyl). The Company has retained all rights to the Staccato system and to its product candidates other than ADASUVE and AZ-104 (Staccato loxapine, low-dose).

Officers and directors

Thomas B. King President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark K. Oki Senior Vice President, Finance, Chief Financial Officer, Secretary, Principal Financial Officer and Principal Accounting Officer
Age: 46
Bio & Compensation  - Reuters
Robert A. Lippe Chief Operating Officer, Executive Vice President - Operations
Age: 50
Bio & Compensation  - Reuters
Edwin S. Kamemoto Ph.D. Executive Vice President - R&D and Quality
Age: 61
Bio & Compensation  - Reuters
Lori H, Takahashi PhD Vice President - Pharmaceutical R&D & Quality
Bio & Compensation  - Reuters
Isaac Stein Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
J. Kevin Buchi Independent Director
Age: 59
Bio & Compensation  - Reuters
Deepika R. Pakianathan Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
J. Leighton Read M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Gordon Ringold Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters